General Information of Drug (ID: DMM0N1F)

Drug Name
AZD-0865 Drug Info
Synonyms AR-H044277
Indication
Disease Entry ICD 11 Status REF
Gastrointestinal disease DE2Z Phase 2 [1]
Cross-matching ID
PubChem CID
9951066
CAS Number
CAS 248919-64-4
TTD Drug ID
DMM0N1F

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [3]
Pantoprazole DMSVOCZ Gastrinoma 2C10.1 Approved [3]
Dexlansoprazole DM1DBV5 Erosive esophagitis DA25.0 Approved [3]
Esomeprazole DM7BN0X Cystic fibrosis CA25 Approved [3]
Vonoprazan DMO6315 Helicobacter infection DA42-DA63 Approved [4]
RQ-00000004 DM9T8OF Gastroesophageal reflux disease DA22.Z Phase 3 [5]
YH-4808 DMCHFB0 Duodenal ulcer DA63 Phase 2 [6]
S-tenatoprazole DMJ1DIB Peptic ulcer DA61 Phase 2 [7]
LEMINOPRAZOLE DMBKNJT Ulcerative colitis DD71 Discontinued in Preregistration [8]
SKF-96067 DMXW1Y3 Peptic ulcer DA61 Discontinued in Phase 3 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric H(+)/K(+) ATPase (Proton pump) TTLOKXP ATP4A_HUMAN; ATP4B_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00206284) A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.. U.S. National Institutes of Health.
2 Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008
5 N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9.
6 Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil.2012 Aug;24(8):697-704.
7 Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in heal... Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62.
8 Vasoinhibitory effect of leminoprazole, a H+,K(+)-ATPase inhibitor, on rat aortic rings. Gen Pharmacol. 1996 Jan;27(1):117-21.
9 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.